{"id":"NCT02819284","sponsor":"Kala Pharmaceuticals, Inc.","briefTitle":"Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease","officialTitle":"A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2017-09","completion":"2017-09","firstPosted":"2016-06-30","resultsPosted":"2020-12-03","lastUpdate":"2021-01-05"},"enrollment":909,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndromes","Keratoconjunctivitis Sicca"],"interventions":[{"type":"DRUG","name":"KPI-121 0.25% Ophthalmic Suspension","otherNames":["Loteprednol etabonate"]},{"type":"DRUG","name":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","otherNames":["Placebo"]}],"arms":[{"label":"KPI-121 0.25% Ophthalmic Suspension","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).","primaryOutcome":{"measure":"Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)","timeFrame":"Baseline/Visit 2 (Day 1) - Visit 4 (Day 15)","effectByArm":[{"arm":"KPI-121 0.25% Ophthalmic Suspension","deltaMin":-0.3812,"sd":0.6056},{"arm":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","deltaMin":-0.2371,"sd":0.62256}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":62,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":452},"commonTop":["Instillation site pain","Eye pruritus","Vision blurred","Eye irritation","Conjunctival hyperaemia"]}}